stella
beta
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD） — Stella
Recruiting
Back to NAFLD (Non-alcoholic Fatty Liver Disease) trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(5 sites)
China
Beijing Tsinghua Changgung Hospital (BTCH) affiliated to Tsinghua University, Beijing, Beijing Municipality
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong
Sinopharm Tongmei General Hospital, Datong, Shanxi
The First Affiliated Hospital to Nankai University, Tianjin, Tianjin Municipality
The First Affiliated Hospital to Wenzhou Medical University, Wenzhou, Zhejiang
View full record on ClinicalTrials.gov